Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Upgraded by Zacks Research to “Hold” Rating

Posted by Alanna Baker on May 27th, 2026

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY – Get Free Report) was upgraded by equities research analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a note issued to investors on Monday,Zacks.com reports.

Separately, The Goldman Sachs Group raised shares of Shionogi & Co., Ltd. Unsponsored ADR to a “hold” rating in a research report on Wednesday, April 8th. Two investment analysts have rated the stock with a Hold rating, According to MarketBeat, the stock presently has an average rating of “Hold”.

Read Our Latest Stock Analysis on Shionogi & Co., Ltd. Unsponsored ADR

Shionogi & Co., Ltd. Unsponsored ADR Price Performance

Shares of OTCMKTS SGIOY opened at $9.33 on Monday. The company has a quick ratio of 5.21, a current ratio of 5.84 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $15.88 billion, a PE ratio of 11.66, a P/E/G ratio of 0.68 and a beta of 0.10. The firm has a fifty day simple moving average of $10.23 and a 200 day simple moving average of $9.86. Shionogi & Co., Ltd. Unsponsored ADR has a twelve month low of $7.65 and a twelve month high of $12.00.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY – Get Free Report) last issued its quarterly earnings data on Tuesday, May 12th. The company reported $0.18 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.15 by $0.03. Shionogi & Co., Ltd. Unsponsored ADR had a net margin of 41.08% and a return on equity of 14.09%. The firm had revenue of $881.71 million during the quarter, compared to analysts’ expectations of $895.52 million. On average, sell-side analysts forecast that Shionogi & Co., Ltd. Unsponsored ADR will post 0.78 EPS for the current year.

About Shionogi & Co., Ltd. Unsponsored ADR

(Get Free Report)

Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that conducts research, development, manufacturing and marketing of prescription drugs and vaccines. Established in the late 19th century, the company has expanded its focus beyond domestic markets to become a global player in pharmaceuticals, with particular expertise in anti-infectives, pain management, cardiovascular and central nervous system disorders.

The company’s product portfolio spans both established and innovative therapies.